June 3, 2011
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501)

TOKYO, Japan, June 3, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,President & CEO: Fuminori Yoshida, “SymBio”) announced today that the Korea Food and Drug
Administration (KFDA) in South Korea approved bendamustine HCI (SyB L-0501) for thetreatment of patients with chronic lymphocytic leukemia and multiple myeloma on May 31, 2011.
Eisai Korea Inc., the subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: HaruoNaito), will promote the product.
In Japan, SymBio received market approval of TREAKISYM® (bendamustine) in October, 2010 for
the treatment of patients with refractory/relapsed low-grade non-Hodgkin’s lymphoma andmantle cell lymphoma. Sales of TREAKISYM® in Japan are rapidly gaining momentum after
launch in December, 2010. In other Asian markets, bendamustine has been approved in HongKong (December, 2009) and Singapore (January, 2010) for the treatment of patients with indolent
non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In addition to South Korea,
bendamustine is also expected to receive market approval this year in Taiwan.
In its pursuit of aspiring to be a leading oncology specialty pharma in Asia Pacific, SymBio's
business in key Asian markets continues to expand as it nimbly develops the use of bendamustinein the hematology space to address the unmet medical needs of patients.

[Please see the following for further information on bendamustine hydrochloride and SymBio]Note to Editors

1. About Bendamustine Hydrochloride (“bendamustine”)
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm,and is currently marketed in Germany under the brand name “Ribomustin®” as a treatment for
non-Hodgkin’s lymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma
has received market authorization in several EU countries for bendamustine under the brandname “Levact®.” In the United States, the drug has been approved by the U.S. Food and Drug
Administration and is marketed as TREANDA® for the treatment of chronic lymphocytic leukemia
and relapsed indolent B-cell non-Hodgkin's lymphoma. SymBio Pharmaceuticals Limited
originally acquired the exclusive right from Astellas Deutschland GmbH (Headquarters: Munich,Germany, formerly Astellas Pharma GmbH) to develop and commercialize bendamustine in Japan(December, 2005), followed by signature of a second license agreement for the exclusive right toChina/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).
2. About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochlorideIndications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused
intravenously over 60 minutes on Days 1 and 2 of repeated 21-day cycles. The
dose may be reduced as deemed appropriate according to the patient’s condition.
3. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, whopreviously served concurrently as Corporate VP of Amgen Ltd. and founding President ofAmgen Japan (currently Takeda Bio Development Center Limited). The company’s underlying
corporate mission is “delivering hope to patients in need” as it aspires to be a leading specialty
pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needsin the areas of oncology, hematology and autoimmune disease.
[Contact]
SymBio Pharmaceuticals Limited.
Investor Relations, Finance and Accounting Department
Tel: +081(0)3 5472 1123
URL: http://www.symbiopharma.com/